Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products

Galera Therapeutics, Inc.

Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.
Reduced rate also applies to Product Payment damages received during the royalty period.
Company has suspended clinical development and commercial readiness for both products.
Purchaser is Blackstone Life Sciences, successor in interest to Clarus Ventures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.